Comparative efficacy and safety of anti-PD-1 therapies used in metastatic colorectal cancer: a systematic review and network meta-analysis

ABSTRACT

Objective: Systemic studies on anti-PD-1 therapy in patients with metastatic colorectal cancer (mCRC) with microsatellite instability or mismatch repair defects are lacking. We aimed to summarize the evidence regarding the efficacy and safety of pembrolizumab, nivolumab, ipilimumab, and tislelizumab in mCRC. Methods: Network meta-analyses (NMAs) can provide comparative efficacy and safety data for clinical decision-making. In this NMA, eligible publications from PubMed, EMBASE, Web of Science, and Cochrane Library from 2016 to April 2023 were identified through a systematic literature review. Literature screening and data extraction were performed according to established criteria. The quality of the literature was evaluated using the Cochrane risk of bias tool, and statistical analysis was performed using Revman5.4 and R language. The main outcome indicators, DCR, ORR, PFS, and OS, were used to evaluate the effectiveness of the drugs, and the main outcome indicators AE and SAE were used to evaluate the safety of each program. Results: Fifteen studies with a sample size of 798 patients were included. In terms of effectiveness, the disease control rate DCR of PD-1 inhibitors was 0.727[95% CI0.654-0.794]; objective response rate ORR was 0.448[95% CI0.382-0.514]; and the 1-year progression-free survival rate was 0.551[95% CI0.458-0.642]. The 1-year overall survival rate was 0.790[95% CI0.705-0.865]. The adverse events associated with anti-PD-1 were 0.567[95% CI0.344-0.778] in terms of safety. The total incidence of grade 3 or higher adverse events was 0.241[95% CI0.174-0.313]. In the subgroup analysis results, the incidence of DCR in the nivolumab + ipilimumab group was 0.826[95% CI0.780-0.869], the ORR was 0.512[95% CI0.377-0.647], and the PFS was 0.668[95% CI0.516-0.804]. The incidence of AE was 0.319 [95% CI0.039-0.700] and SAE was 0.294 [95% CI0.171-0.433]... (AU)